164 related articles for article (PubMed ID: 37904008)
1. Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study.
Nakamoto S; Shien T; Itoh M; Yamamoto Y; Ohsumi S; Yoshitomi S; Hikino H; Miyoshi K; Notsu A; Taira N; Doihara H; Ikeda M
Clin Exp Med; 2023 Dec; 23(8):5129-5138. PubMed ID: 37904008
[TBL] [Abstract][Full Text] [Related]
2. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Notsu A
Sci Rep; 2021 Mar; 11(1):6328. PubMed ID: 33737682
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
Patel DA; Xi J; Luo J; Hassan B; Thomas S; Ma CX; Campian JL
Breast Cancer Res Treat; 2019 Apr; 174(2):443-452. PubMed ID: 30604000
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
6. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
[TBL] [Abstract][Full Text] [Related]
9. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
11. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
Li M; Spakowicz D; Burkart J; Patel S; Husain M; He K; Bertino EM; Shields PG; Carbone DP; Verschraegen CF; Presley CJ; Otterson GA; Kendra K; Owen DH
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2541-2546. PubMed ID: 31367835
[TBL] [Abstract][Full Text] [Related]
12. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer.
Masuda T; Ueo H; Okumura Y; Kai Y; Ando Y; Masuguchi K; Kitagawa M; Kitagawa A; Hayashi N; Tsuruda Y; Hisamatsu Y; Suehiro S; Ohmura H; Fujiyoshi K; Tanaka F; Mimori K
Cancer Genomics Proteomics; 2023; 20(2):182-194. PubMed ID: 36870689
[TBL] [Abstract][Full Text] [Related]
14. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
18. Increased neutrophil-lymphocyte ratio independently predicts poor survival in non-metastatic triple-negative breast cancer patients.
Qiu X; Song Y; Cui Y; Liu Y
IUBMB Life; 2018 Jun; 70(6):529-535. PubMed ID: 29707892
[TBL] [Abstract][Full Text] [Related]
19. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
[TBL] [Abstract][Full Text] [Related]
20. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
